Ezetimibe and Rosuvastatin Interaction
Ezetimibe and Rosuvastatin have a synergistic interaction with 95% confidence. Rosuvastatin and ezetimibe target complementary pathways in cholesterol metabolism -- rosuvastatin inhibits hepatic synthesis while ezetimibe blocks intestinal absorption. The combination (available as the fixed-dose product Roszet) provides an additional 15-20% LDL reduction beyond rosuvastatin alone. Particularly useful for AAS users whose lipids remain elevated despite statin monotherapy, or for those running especially hepatotoxic oral stacks. Both compounds affect the heart, so monitoring these systems is recommended.
Compound Profiles
Ezetimibe
Cholesterol Absorption Inhibitor | Lipid Management On Cycle
Ezetimibe selectively inhibits the NPC1L1 transporter protein located on the luminal surface of enterocytes in the jejunum of the small intestine. NPC1L1 is the critical gateway for intestinal cholesterol absorption, responsible for uptaking both dietary cholesterol and the much larger pool of biliary cholesterol that is recirculated through the enterohepatic cycle.
View full profileRosuvastatin
HMG-CoA Reductase Inhibitor | Statin for Lipid Management
Rosuvastatin competitively inhibits HMG-CoA reductase, the rate-limiting enzyme in the mevalonate pathway responsible for hepatic cholesterol synthesis. By blocking this enzyme, rosuvastatin reduces intracellular cholesterol in hepatocytes, which triggers upregulation of LDL receptor expression on the liver cell surface.
View full profileCombined Organ Load
Shared Safety Flags
Frequently Asked Questions
Can I take Ezetimibe with Rosuvastatin?
Yes, Ezetimibe and Rosuvastatin can generally be taken together. Rosuvastatin and ezetimibe target complementary pathways in cholesterol metabolism -- rosuvastatin inhibits hepatic synthesis while ezetimibe blocks intestinal absorption. The combination (available as the fixed-dose product Roszet) provides an additional 15-20% LDL reduction beyond rosuvastatin alone. Particularly useful for AAS users whose lipids remain elevated despite statin monotherapy, or for those running especially hepatotoxic oral stacks.
Is Ezetimibe and Rosuvastatin safe together?
Based on documented research, this combination is considered synergistic. However, shared safety flags include: hepatotoxic, lipid disrupting, teratogenic. Monitor accordingly.
What are the interactions between Ezetimibe and Rosuvastatin?
Rosuvastatin and ezetimibe target complementary pathways in cholesterol metabolism -- rosuvastatin inhibits hepatic synthesis while ezetimibe blocks intestinal absorption. The combination (available as the fixed-dose product Roszet) provides an additional 15-20% LDL reduction beyond rosuvastatin alone. Particularly useful for AAS users whose lipids remain elevated despite statin monotherapy, or for those running especially hepatotoxic oral stacks. This assessment has 95% confidence and is based on documented research data.
How should I time Ezetimibe and Rosuvastatin?
Ezetimibe has a half-life of ~22 hours and Rosuvastatin has a half-life of ~19 hours. No specific timing requirements identified for this combination, but separating administration can help monitor individual effects.
This interaction analysis is compiled from research literature and pharmacological mechanism data. Always consult a healthcare professional before combining compounds.